BUY SAGILITY LIMITED — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred Swing (≤2wk))26 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·7 Sept · yesterday
3 advisors have active short-term BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·5 Sept · 3d ago
Sagility approves ₹0.10 final dividend, reappoints Hari Gopalakrishnan
NewsGoogle News·21 Aug · 2w ago
Sagility Limited Approves Final Dividend for the Financial Year Ended on 31 March 2026
NewsGoogle News·21 Aug · 2w ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on SAGILITY
- BUY — Siddharth Khemka, Motilal Oswal23 Oct 2026 · ~1 year · target ₹57 · Active
- BUY — Siddharth Rai Mangala23 Oct 2026 · ~2 weeks · target ₹48 · SL hit
- BUY — ICICI Securities23 Oct 2026 · ~1 year · target ₹55 · Active
- BUY — J.P. Morgan23 Oct 2026 · ~1 year · target ₹60 · Active
- BUY — Jefferies India23 Oct 2026 · ~1 year · target ₹59 · Active
More from Manas Jaiswal
- BUY Ajanta Pharma23 Oct 2026 · Same day · target ₹3,425 · SL hit
- BUY Torrent Pharmaceuticals23 Oct 2026 · Same day · target ₹4,725 · SL hit
- BUY SAGILITY23 Oct 2026 · ~2 weeks · target ₹50 · SL hit
- BUY Zydus Lifesciences22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY IPCA Laboratories22 Oct 2026 · ~2 weeks · target ₹2,000 · Active

